HbA1c variability is independently associated with progression of diabetic kidney disease in an urban multi-ethnic cohort of people with type 1 diabetes.

IF 8.4 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetologia Pub Date : 2024-09-01 Epub Date: 2024-06-20 DOI:10.1007/s00125-024-06197-2
Ananya Muthukumar, Layla Badawy, Anastasios Mangelis, Prashant Vas, Stephen Thomas, Aicha Gouber, Salma Ayis, Janaka Karalliedde
{"title":"HbA<sub>1c</sub> variability is independently associated with progression of diabetic kidney disease in an urban multi-ethnic cohort of people with type 1 diabetes.","authors":"Ananya Muthukumar, Layla Badawy, Anastasios Mangelis, Prashant Vas, Stephen Thomas, Aicha Gouber, Salma Ayis, Janaka Karalliedde","doi":"10.1007/s00125-024-06197-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims/hypothesis: </strong>The role of HbA<sub>1c</sub> variability in the progression of diabetic kidney disease is unclear, with most studies to date performed in White populations and limited data on its role in predicting advanced kidney outcomes. Our aim was to evaluate if long-term intra-individual HbA<sub>1c</sub> variability is a risk factor for kidney disease progression (defined as an eGFR decline of ≥50% from baseline with a final eGFR of <30 ml/min per 1.73 m<sup>2</sup>) in an ethnically heterogeneous cohort of people with type 1 diabetes with a preserved eGFR ≥45 ml/min per 1.73 m<sup>2</sup> at baseline.</p><p><strong>Methods: </strong>Electronic health record data from people attending outpatient clinics between 2004 and 2018 in two large university hospitals in London were collected. HbA<sub>1c</sub> variability was assessed using three distinct methods: (1) SD of HbA<sub>1c</sub> (SD-HbA<sub>1c</sub>); (2) visit-adjusted SD (adj-HbA<sub>1c</sub>): SD-HbA<sub>1c</sub>/√n/(n-1), where n is the number of HbA<sub>1c</sub> measurements per participant; and (3) CV (CV-HbA<sub>1c</sub>): SD-HbA<sub>1c</sub>/mean-HbA<sub>1c</sub>. All participants had six or more follow-up HbA<sub>1c</sub> measurements. The eGFR was measured using the Chronic Kidney Disease Epidemiology Collaboration equation and clinical/biochemical results from routine care were extracted from electronic health records.</p><p><strong>Results: </strong>In total, 3466 participants (50% female, 78% White, 13% African Caribbean, 3% Asian and 6% of mixed heritage or self-reporting as 'other') were followed for a median (IQR) of 8.2 (4.2-11.6) years. Of this cohort, 249 (7%) showed kidney disease progression. Higher HbA<sub>1c</sub> variability was independently associated with a higher risk of kidney disease progression, with HRs (95% CIs) of 7.76 (4.54, 13.26), 2.62 (1.75, 3.94) and 5.46 (3.40, 8.79) (lowest vs highest HbA<sub>1c</sub> variability quartile) for methods 1-3, respectively. Increasing age, baseline HbA<sub>1c</sub>, systolic BP and urinary albumin/creatinine ratio were also associated with kidney disease progression (p<0.05 for all). African Caribbean ethnicity was associated with an increased risk of kidney disease progression (HR [95% CI] 1.47 [1.09, 1.98], 1.76 [1.32, 2.36] and 1.57 [1.17, 2.12] for methods 1-3, respectively) and this effect was independent of glycaemic variability and other traditional risk factors.</p><p><strong>Conclusions/interpretation: </strong>We observed an independent association between HbA<sub>1c</sub> variability, evaluated using three distinct methods, and significant kidney disease progression in a multi-ethnic type 1 diabetes cohort. Further studies are needed to elucidate the mechanisms that may explain our results and evaluate if HbA<sub>1c</sub> variability is a modifiable risk factor for preventing diabetic kidney disease progression.</p>","PeriodicalId":11164,"journal":{"name":"Diabetologia","volume":null,"pages":null},"PeriodicalIF":8.4000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11410835/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00125-024-06197-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Aims/hypothesis: The role of HbA1c variability in the progression of diabetic kidney disease is unclear, with most studies to date performed in White populations and limited data on its role in predicting advanced kidney outcomes. Our aim was to evaluate if long-term intra-individual HbA1c variability is a risk factor for kidney disease progression (defined as an eGFR decline of ≥50% from baseline with a final eGFR of <30 ml/min per 1.73 m2) in an ethnically heterogeneous cohort of people with type 1 diabetes with a preserved eGFR ≥45 ml/min per 1.73 m2 at baseline.

Methods: Electronic health record data from people attending outpatient clinics between 2004 and 2018 in two large university hospitals in London were collected. HbA1c variability was assessed using three distinct methods: (1) SD of HbA1c (SD-HbA1c); (2) visit-adjusted SD (adj-HbA1c): SD-HbA1c/√n/(n-1), where n is the number of HbA1c measurements per participant; and (3) CV (CV-HbA1c): SD-HbA1c/mean-HbA1c. All participants had six or more follow-up HbA1c measurements. The eGFR was measured using the Chronic Kidney Disease Epidemiology Collaboration equation and clinical/biochemical results from routine care were extracted from electronic health records.

Results: In total, 3466 participants (50% female, 78% White, 13% African Caribbean, 3% Asian and 6% of mixed heritage or self-reporting as 'other') were followed for a median (IQR) of 8.2 (4.2-11.6) years. Of this cohort, 249 (7%) showed kidney disease progression. Higher HbA1c variability was independently associated with a higher risk of kidney disease progression, with HRs (95% CIs) of 7.76 (4.54, 13.26), 2.62 (1.75, 3.94) and 5.46 (3.40, 8.79) (lowest vs highest HbA1c variability quartile) for methods 1-3, respectively. Increasing age, baseline HbA1c, systolic BP and urinary albumin/creatinine ratio were also associated with kidney disease progression (p<0.05 for all). African Caribbean ethnicity was associated with an increased risk of kidney disease progression (HR [95% CI] 1.47 [1.09, 1.98], 1.76 [1.32, 2.36] and 1.57 [1.17, 2.12] for methods 1-3, respectively) and this effect was independent of glycaemic variability and other traditional risk factors.

Conclusions/interpretation: We observed an independent association between HbA1c variability, evaluated using three distinct methods, and significant kidney disease progression in a multi-ethnic type 1 diabetes cohort. Further studies are needed to elucidate the mechanisms that may explain our results and evaluate if HbA1c variability is a modifiable risk factor for preventing diabetic kidney disease progression.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在一个 1 型糖尿病患者的城市多种族队列中,HbA1c 变异与糖尿病肾病的进展密切相关。
目的/假设:HbA1c 变异性在糖尿病肾病进展中的作用尚不清楚,迄今为止的大多数研究都是在白种人中进行的,有关其在预测晚期肾病结果中的作用的数据有限。我们的目的是评估在基线eGFR≥45 ml/min per 1.73 m2的1型糖尿病患者种族异质性队列中,长期个体内HbA1c变异性是否是肾脏疾病进展(定义为eGFR从基线下降≥50%,最终eGFR为2)的风险因素:收集了伦敦两家大型大学医院2004年至2018年间门诊患者的电子健康记录数据。使用三种不同的方法评估 HbA1c 变异性:(1)HbA1c 的 SD(SD-HbA1c);(2)就诊调整 SD(adj-HbA1c):SD-HbA1c/√n/(n-1),其中 n 为每位参与者的 HbA1c 测量次数;(3) CV(CV-HbA1c):SD-HbA1c/mean-HbA1c 。所有参与者都进行了六次或六次以上的随访 HbA1c 测量。eGFR 采用慢性肾脏病流行病学协作方程进行测量,常规护理的临床/生化结果从电子健康记录中提取:共对 3466 名参与者(50% 为女性,78% 为白人,13% 为非洲加勒比海人,3% 为亚洲人,6% 为混合血统或自称 "其他")进行了中位数(IQR)为 8.2(4.2-11.6)年的随访。其中 249 人(7%)出现肾病进展。HbA1c 变异性越高,肾病进展的风险越高,方法 1-3 的 HRs(95% CIs)分别为 7.76(4.54,13.26)、2.62(1.75,3.94)和 5.46(3.40,8.79)(最低与最高 HbA1c 变异性四分位数)。年龄、基线 HbA1c、收缩压和尿白蛋白/肌酐比值的增加也与肾病进展有关(p结论/解释:我们在一个多种族 1 型糖尿病队列中观察到,使用三种不同方法评估的 HbA1c 变异与肾脏疾病的显著进展之间存在独立关联。我们需要进一步研究,以阐明可能解释我们的结果的机制,并评估 HbA1c 变异性是否是预防糖尿病肾病进展的可调节风险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Diabetologia
Diabetologia 医学-内分泌学与代谢
CiteScore
18.10
自引率
2.40%
发文量
193
审稿时长
1 months
期刊介绍: Diabetologia, the authoritative journal dedicated to diabetes research, holds high visibility through society membership, libraries, and social media. As the official journal of the European Association for the Study of Diabetes, it is ranked in the top quartile of the 2019 JCR Impact Factors in the Endocrinology & Metabolism category. The journal boasts dedicated and expert editorial teams committed to supporting authors throughout the peer review process.
期刊最新文献
Type 2 diabetes pathway-specific polygenic risk scores elucidate heterogeneity in clinical presentation, disease progression and diabetic complications in 18,217 Chinese individuals with type 2 diabetes The metabolic and circadian signatures of gestational diabetes in the postpartum period characterised using multiple wearable devices Prediabetes is associated with elevated risk of clinical outcomes even without progression to diabetes A WFS1 variant disrupting acceptor splice site uncovers the impact of alternative splicing on beta cell apoptosis in a patient with Wolfram syndrome Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013–2019
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1